Stockhub

Vivoryon Therapeutics N.V.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

17 August 2022

  • curprev 12:2312:23, 17 August 2022 >Paris 1,540 bytes +1,540 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in th..."
Retrieved from "https://stockhub.co/research/Vivoryon_Therapeutics_N.V."